This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutEnbrel commitment to inflammation careDosingDosingEnbrel dosing and administrationMyClic pre-filled penPre-filled syringeMyClic administrationPowder and solventEfficacy and SafetyEfficacy and SafetyEnbrel therapeutic indicationsRheumatoid arthritisJuvenile idiopathic arthritisPsoriatic arthritis
Ankylosing spondylitisPlaque psoriasisSupport & ResourcesSupport & ResourcesEnbrel patient supportOrder patient materialsEnbrel: Sleeve for MyClic pre-filled pensVideosMaterials

Information on how to access Enbrel® (etanercept) and Maxtrex (methotrexate) prescribing information and adverse event reporting can be found at the bottom of the page.

Explore the Licensed  Indications for Enbrel® (etanercept)

Enbrel (etanercept) licenced indications

Enbrel (etanercept) is a fully human soluble Tumour Necrosis Factor (TNF) receptor protein, indicated to treat; rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis1

Enbrel commitment to inflammation care

Pfizer is committed to using our extensive experience to support and transform the lives of patients living with debilitating inflammatory diseases. Take a look at our Inflammation page to see how we have supported patients for over 20 years.

 Explore Enbrel in inflammation care  
Loading

Enbrel therapeutic indications

Take a look at Enbrels efficacy and safety information when treating Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis, Non-radiographic axial spondyloarthritis, Plaque psoriasis, Paediatric plaque psoriasis1

Explore Enbrels' UK licenses
LoadingExplore more

Enbrel dosing and administration

Learn about the recommended dosing for Enbrel and the devices available to your patients to help their at-home management

Read about Enbrel MyClic administration
Loading

Enbrel Patient Support

See what online support your patients have access to

Explore Enbrel Patient Support
Loading

Further Information:

To keep up to date on NICE guidance. See NICE guidance on Enbrel.
Learn details about the European Public Assessment report (EPAR) for Enbrel.

 

Prescribing information

Enbrel (etanercept) prescribing information,  Enbrel PI
Maxtrex (methotrexate) prescribing information, Maxtrex PI 
 
ReferencesEnbrel (etanercept) Summary of Product Characteristics.
PP-ENB-GBR-1121. January 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​